- Home
- BOLT vs ALLR Comparison
BOLT vs ALLR Comparison
Compare BOLT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- ALLR
- Stock Information
- Founded
- BOLT 2015
- ALLR 2004
- Country
- BOLT United States
- ALLR United States
- Employees
- BOLT N/A
- ALLR N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- ALLR Health Care
- Exchange
- BOLT Nasdaq
- ALLR Nasdaq
- Market Cap
- BOLT 16.8M
- ALLR 15.8M
- IPO Year
- BOLT 2021
- ALLR N/A
- Fundamental
- Price
- BOLT $5.50
- ALLR $0.96
- Analyst Decision
- BOLT Buy
- ALLR Strong Buy
- Analyst Count
- BOLT 3
- ALLR 1
- Target Price
- BOLT $50.00
- ALLR $9.00
- AVG Volume (30 Days)
- BOLT 16.5K
- ALLR 492.5K
- Earning Date
- BOLT 08-19-2025
- ALLR 08-19-2025
- Dividend Yield
- BOLT N/A
- ALLR N/A
- EPS Growth
- BOLT N/A
- ALLR N/A
- EPS
- BOLT N/A
- ALLR N/A
- Revenue
- BOLT $3,638,000.00
- ALLR N/A
- Revenue This Year
- BOLT N/A
- ALLR N/A
- Revenue Next Year
- BOLT $13.62
- ALLR N/A
- P/E Ratio
- BOLT N/A
- ALLR N/A
- Revenue Growth
- BOLT N/A
- ALLR N/A
- 52 Week Low
- BOLT $5.20
- ALLR $0.61
- 52 Week High
- BOLT $14.36
- ALLR $6.00
- Technical
- Relative Strength Index (RSI)
- BOLT 40.87
- ALLR 44.74
- Support Level
- BOLT $5.30
- ALLR $0.93
- Resistance Level
- BOLT $5.94
- ALLR $1.06
- Average True Range (ATR)
- BOLT 0.31
- ALLR 0.06
- MACD
- BOLT -0.04
- ALLR -0.01
- Stochastic Oscillator
- BOLT 13.34
- ALLR 12.46
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.